Rebecca Bhatt

Rebecca Bhatt applies ctDNA analysis to monitor treatment response and detect resistance mutations in metastatic breast cancer. Her research has characterized serial ctDNA dynamics as predictors of progression-free survival in hormone receptor-positive breast cancer treated with CDK4/6 inhibitors. She has identified ESR1 and PIK3CA mutations emerging in ctDNA as early resistance biomarkers guiding treatment switch decisions. Her prospective ctDNA monitoring studies have demonstrated clinical utility in adapting therapy before radiographic progression in breast cancer.